FindTrial
Sign In

Predictive value of receptor interaction protein kinase 3 (RIPK3) in contrast-induced acute kidney injury after coronary intervention

Predictive value of receptor interaction protein kinase 3 (RIPK3) in contrast-induced acute kidney injury after coronary intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056028
Enrollment
Unknown
Registered
2022-01-31
Start date
2022-03-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced acute kidney injury

Interventions

CI-AKI group:Nil
non CI-AKI group:Nil

Sponsors

Zhongda Hospital of Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this trial and sign the informed consent; 2. Aged 18 - 85 years; 3. Proposed coronary intervention; 4. AGEF score > 1.16; 5. No related contraindications.

Exclusion criteria

Exclusion criteria: 1. There is a history of contrast agent allergy; 2. Lactation, pregnancy; 3. Existing or suspected acute kidney injury; 4. Those who used contrast agents and nephrotoxic drugs within 1 week before enrollment; 5. Severe renal insufficiency requiring hemodialysis; 6. Use of aortic balloon counterpulsation, acute heart failure, liver failure, connective tissue disease, tumor, serious infectious disease, cardiogenic shock in hospital, sudden cardiac death, etc.

Design outcomes

Primary

MeasureTime frame
The incedence of CI-aki;—

Secondary

MeasureTime frame
Adverse events in postoperative;—

Countries

China

Contacts

Public ContactYan Gaoliang

Zhongda Hospital of Southeast University

yanshipingguo@163.com+86 18761890380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026